BBP-812

About BridgeBio Pharma

BridgeBio Pharma operates as a diversified biotech platform targeting genetic diseases through its innovative hub-and-spoke organizational model. The company has advanced multiple programs into Phase 3 trials, including acoramidis for transthyretin amyloidosis, encaleret for hypoparathyroidism, and infigratinib for achondroplasia. With over 2,000 patients enrolled in clinical trials globally and a pipeline consisting of 100% first-in-class or best-in-class therapies, BridgeBio has established itself as a leader in genetic medicine development.

Therapeutic Areas